Cost–effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease

References

• Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med.354, 131–140 (2006).
   PubMed Web of Science ®Google Scholar
• Frei U, Schober-Halstenberg HJ. [Annual Report of the German Renal Registry 2005/06. QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy]. Quasi-Niere, Berlin, Germany (2006).
   Google Scholar
• Icks A, Haastert B, Gandjour A et al. Costs of dialysis – a regional population-based analysis. Nephrol. Dial. Transplant.25, 1647–1652 (2010).
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med.334, 939–945 (1996).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Benini R et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J. Am. Soc. Nephrol.9, 2096–2101 (1998).
   PubMed Web of Science ®Google Scholar
• The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet349, 1857–1863 (1997).
   PubMed Web of Science ®Google Scholar
• Hogan TJ, Elliott WJ, Seto AH et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics20, 37–47 (2002).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med.160, 685–693 (2000).
   PubMed Web of Science ®Google Scholar
• Moser M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J. Am. Coll. Cardiol.29, 1414–1421 (1997).
   PubMed Web of Science ®Google Scholar
• Brunner HR. ACE inhibitors in renal disease. Kidney Int.42, 463–479 (1992).
   PubMed Web of Science ®Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med.11, 234–242 (1992).
   Google Scholar
• Keane FW, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann. Intern. Med.111, 503–516 (1989).
   PubMed Web of Science ®Google Scholar
• Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation14, 1411–1420 (1998).
   Google Scholar
• Ihle BU, Whitworth JA, Shahinfar S et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am. J. Kidney Dis.27, 489–449 (1996).
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB et al. (Eds). Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, USA (1996).
   Google Scholar
• Adarkwah CC, Gandjour A. Cost–effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed Type 2 diabetes in Germany. Int. J. Technol. Assess. Healthcare26, 62–70 (2010).
   PubMed Web of Science ®Google Scholar
• Terajima T, Yamagata S, Satoh N, Ueda S. Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency. Pharm. Ther.28, 98–112 (2003).
   Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from the retrospective analysis of disease. J. Natl Cancer Inst.22, 719–748 (1959).
   PubMed Web of Science ®Google Scholar
• Kuntz KM, Weinstein MC. Modelling in economic evaluation. In: Economic Evaluation in Healthcare: Merging Theory with Practice. Drummond M, McGuire A, (Eds). Oxford University Press, NY, USA (2005).
   Google Scholar
• Hemmelgarn BR, Manns BJ, Lloyd A et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA303, 423–429 (2010).
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Wittenborn JS, Segel JE et al.; Centers for Disease Control and Prevention CKD Initiative. A health policy model of CKD: 2. The cost–effectiveness of microalbuminuria screening. Am. J. Kidney Dis.55, 463–473 (2010).
   PubMed Web of Science ®Google Scholar
• Fryback DG, Dasbach EJ, Klein R et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med. Decis. Making13, 89–102 (1993).
   PubMed Web of Science ®Google Scholar
• Churchill DN, Torrance GW, Taylor DW et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin. Invest. Med.10, 14–20 (1987).
   PubMed Web of Science ®Google Scholar
• Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J. Health Serv. Res. Policy9, 43–50 (2004).
   PubMedGoogle Scholar
• Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J. Health Econ.16, 155–175 (1997).
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P et al. Valuing health states: a comparison of methods. J. Health Econ.15, 209–231 (1996).
   PubMed Web of Science ®Google Scholar
• [Uniform Value Scale for Physician Services]. Kassenärztliche Bundesvereinigung, Berlin, Germany (2009).
   Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis.39(2 Suppl. 1), S1–S266 (2002).
   PubMed Web of Science ®Google Scholar
• Harris D, Thomas M, Johnson D et al.; Caring for Australasians with Renal Impairment (CARI). The CARI guidelines. Prevention of progression of kidney disease. Nephrology (Carlton)11(Suppl. 1), S2–S197 (2006).
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians. Chronic kidney disease. National clinical guideline for early identification and management in adults in primary and secondary care. Royal College of Physicians, London, UK (2008).
   Google Scholar
• Nebel M. [Costs of renal replacement therapies in Germany in 1999]. Nieren- und Hochdruckkrankheiten3, 85–92 (2002).
   Google Scholar
• John JA, Whitaker D, Johnson DG. Statistical Thinking in Business (2nd Edition). Chapman & Hall/CRC, Boca Raton, FL, USA (2006).
   Google Scholar
• Palmer AJ, Valentine WJ, Chen R et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with Type 2 diabetes and hypertension in the USA. Nephrol. Dial. Transplant.23, 1216–1223 (2008).
   PubMed Web of Science ®Google Scholar
• Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens.21, 1983–1992 (2003).
   PubMed Web of Science ®Google Scholar
• Zidek W, Düsing R, Haller H et al.; German Society of Hypertension. [New recommendations of the German Hypertension League for the drug treatment of hypertension]. Dtsch Med. Wochenschr.128, 2468–2469 (2003).
   PubMed Web of Science ®Google Scholar
• Cardillo C, Mores N, Motolese M et al. Effects of benazepril on stress testing blood pressure in essential hypertension. Am. J. Cardiol.73, 368–373 (1994).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Wilmer WA, Rovin BH, Hebert CJ et al. Management of glomerular proteinuria: a commentary. J. Am. Soc. Nephrol.14, 3217–3232 (2003).
   PubMed Web of Science ®Google Scholar
• Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int.59, 1211–1226 (2001).
   PubMed Web of Science ®Google Scholar
• Praga M. Slowing the progression of renal failure. Kidney Int. Suppl.80, 18–22 (2002).
   Google Scholar
• Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet361, 117–124 (2003).
   PubMed Web of Science ®Google Scholar
• Perna A, Ruggenenti P, Testa A et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int.57, 274–281 (2000).
   PubMed Web of Science ®Google Scholar
• Neubauer G, Breu M, Pommer W. [Prospective cost-comparison study on centre haemodialysis and peritoneal dialysis in Germany]. Institut für Gesundheitsökonomik(ifG), München, Germany (2000).
   Google Scholar